ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999

Conferees Set $1.991 Bil. NCI Budget, Ax Earmark For Breast Cancer, But Find $210 Mil. In Defense

October 9, 1992

Scientists Falsified Research, ORI Says

July 5, 1996

Competing Core, P01 Grants Held To 7% Increases To Help Spread $$ Around

December 7, 1979

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

BMT Ok For some Stage IV Breast Cancer, Blues Advisor Say

March 8, 1996